ANAVEX LIFE SCIENCES CORP. 8-K

What Happened

• Anavex Life Sciences Corp. announced in an 8-K that Felix Lauscher, who had served as Chief Operating Officer since March 1, 2026, departed the company effective May 11, 2026 as part of a reorganization following the appointment of Dr. Terrie Kellmeyer as Interim CEO.
• Under his employment terms, Mr. Lauscher had an annual base salary of $264,000 (paid pro rata for his service). He was granted 50,000 stock options; 45,833 of those options were immediately forfeited upon his departure and 4,167 vested on March 31, 2026 and remain exercisable until August 9, 2026 at $4.69 per share.

Key Details

• Departure date: May 11, 2026; COO since March 1, 2026.
• Annual base salary while employed: $264,000 (prorated).
• Equity: 50,000 options granted → 45,833 forfeited, 4,167 vested (exercisable through Aug 9, 2026) at $4.69/share.
• Separation payment: offered two weeks’ salary in exchange for execution (and non-revocation) of a general release.

Why It Matters

• Executive turnover can affect company operations and investor sentiment; this filing documents a leadership change tied to a broader reorganization under the interim CEO.
• Financial impact appears limited: severance is modest (two weeks’ pay) and most equity awards were forfeited, so near-term cash and dilution effects are minimal based on this filing.
• Investors should watch for further leadership updates or strategy announcements from the company in future filings and communications.